BRIEF-FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Reuters2026/09/24 19:21Sept 24 (Reuters) - FDA:
FDA APPROVES BELZUTIFAN IN COMBINATION WITH LENVATINIB FOR ADVANCED RENAL CELL CARCINOMA WITH A CLEAR CELL COMPONENT
FDA: RECOMMENDED DOSAGE IS 20 MG OF LENVATINIB IN COMBINATION WITH 120 MG OF BELZUTIFAN ONCE DAILY UNTIL DISEASE PROGRESSION OR UNACCEPTABLE TOXICITY
Further company coverage: MRK.N
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CME Group Launches Micro Futures for SUI and Sui Ecosystem DeFi
SEC Crypto Asset Rules Clarify Token Buybacks and Upgrades
Cathie Wood Brings $1.3 Billion Fund Holding SpaceX and OpenAI Onchain
Ethereum’s $2,540 Retest Becomes Key Test for the Rally
Crypto prices
More
